Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$301.32 USD

301.32
111,116

+1.52 (0.51%)

Updated Oct 2, 2024 02:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.

Here's Why You Should Hold on to Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

PDCO or WST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PDCO vs. WST: Which Stock Is the Better Value Option?

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Higher revenues and growth in worldwide da Vinci procedure volume benefit Intuitive Surgical's (ISRG) preliminary Q4 results.

Veeva Systems Boosts Product Portfolio With New Application

by Zacks Equity Research

Veeva Systems (VEEV) introduces Veeva Vault Payments, which is likely to bolster the company's already robust product portfolio.

Varian (VAR) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Varian (VAR) gains from several positive developments.

Here's Why You Should Invest in HMS Holdings (HMSY) Stock Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services.

Amedisys Gains on Favorable Demography, New Hospice Buyouts

by Zacks Equity Research

Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.

Exact Sciences Rides on Cologuard, Eyes Merger Synergies

by Zacks Equity Research

Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

by Zacks Equity Research

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

Here's Why You Should Add STERIS (STE) to Portfolio Now

by Zacks Equity Research

Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Urmimala Biswas headshot

LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds

by Urmimala Biswas

LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).

Here's Why You Should Hold on to Phibro (PAHC) Stock Now

by Zacks Equity Research

Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.

Illumina Stock Slips on Pacific Biosciences Deal Termination

by Zacks Equity Research

Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

by Zacks Equity Research

Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.

Here's Why You Should Hold on to Insulet (PODD) Stock Now

by Zacks Equity Research

Investors can retain Insulet (PODD) stock for now on the back of its solid prospects.

Here's Why You Should Hold on to Intersect ENT (XENT) for Now

by Zacks Equity Research

Investors can retain Intersect ENT (XENT) stock for now, courtesy of its solid prospects.

Here's Why You Should Hold on to Intuitive Surgical for Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.

Here's Why You Should Invest in Patterson Companies Stock Now

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

    HMS Holdings Acquires Nebraska-Based Intrado's Accent Unit

    by Zacks Equity Research

    The latest deal is likely to boost HMS Holdings' (HMSY) Payment Integrity solutions business.

    Here's Why You Should Hold on to Masimo (MASI) Stock Now

    by Zacks Equity Research

    Masimo (MASI) raises revenue and earnings guidance for 2019.

    Trina Mukherjee headshot

    6 MedTech Stocks That are Set to Beat the Market in 2020

    by Trina Mukherjee

    Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

    Masimo (MASI) Expands Partnership with Texas-Based Drager

    by Zacks Equity Research

    Masimo (MASI) sees a slew of developments in recent times.